Psychological resilience and related influencing factors in postoperative non‐small cell lung cancer patients: A cross‐sectional study

2020 ◽  
Vol 29 (11) ◽  
pp. 1815-1822
Author(s):  
Shihao Chen ◽  
Ranran Mei ◽  
Chuxia Tan ◽  
Xuting Li ◽  
Chenxi Zhong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cross Sectional Study ◽  
Small Cell ◽  
Psychological Resilience ◽  
Sectional Study ◽  
Small Cell Lung ◽  
Cross Sectional ◽  
Lung Cancer Patients

A cross-sectional study examining the expression of splice variants K-RAS4A and K-RAS4B in advanced non-small-cell lung cancer patients

Lung Cancer ◽  
2018 ◽  
Vol 116 ◽  
pp. 7-14
Author(s):  
Veronica Aran ◽  
Pedro Masson Domingues ◽  
Fabiane Carvalho de Macedo ◽  
Carlos Augusto Moreira de Sousa ◽  
Tatiane Caldas Montella ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Splice Variants ◽  
Cross Sectional Study ◽  
Small Cell ◽  
Sectional Study ◽  
Small Cell Lung ◽  
Cross Sectional ◽  
Lung Cancer Patients

A cross-sectional study of vitamin intake in postoperative non-small cell lung cancer patients

1998 ◽  
Vol 68 (4) ◽  
pp. 231-236 ◽  
Author(s):  
Aminah Jatoi ◽  
Benedict D.T. Daly ◽  
Gertrude Kramer ◽  
Joel B. Mason
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cross Sectional Study ◽  
Small Cell ◽  
Sectional Study ◽  
Small Cell Lung ◽  
Cross Sectional ◽  
Lung Cancer Patients ◽  
Vitamin Intake

scholarly journals Human papillomavirus is not associated to non-small cell lung cancer: data from a prospective cross-sectional study

2019 ◽  
Vol 14 (1) ◽  
Author(s):  
Estela Maria Silva ◽  
Vânia Sammartino Mariano ◽  
Paula Roberta Aguiar Pastrez ◽  
Miguel Cordoba Pinto ◽  
Emily Montosa Nunes ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Human Papillomavirus ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cross Sectional Study ◽  
Small Cell ◽  
Sectional Study ◽  
Small Cell Lung ◽  
Cross Sectional ◽  
Cancer Data

The symptom burden of non-small cell lung cancer in the USA: a real-world cross-sectional study

2013 ◽  
Vol 22 (1) ◽  
pp. 181-187 ◽  
Author(s):  
Shrividya Iyer ◽  
Adam Roughley ◽  
Alex Rider ◽  
Gavin Taylor-Stokes
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Real World ◽  
Symptom Burden ◽  
Cross Sectional Study ◽  
Small Cell ◽  
Sectional Study ◽  
Small Cell Lung ◽  
Cross Sectional ◽  
The Usa

scholarly journals Total Psoas Area and Total Muscular Parietal Area Affect Long-Term Survival of Patients Undergoing Pneumonectomy for Non-Small Cell Lung Cancer

Cancers ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1888
Author(s):  
Elisa Daffrè ◽  
Mathilde Prieto ◽  
Katharina Martini ◽  
Trieu-Nghi Hoang-Thi ◽  
Nara Halm ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Fatty Infiltration ◽  
Small Cell ◽  
Small Cell Lung ◽  
Muscle Area ◽  
Cross Sectional ◽  
Lung Cancer Patients

There is no standardization in methods to assess sarcopenia; in particular the prognostic significance of muscular fatty infiltration in lung cancer patients undergoing surgery has not been evaluated so far. We thus performed several computed tomography (CT)-based morphometric measurements of sarcopenia in 238 consecutive non-small cell lung-cancer patients undergoing pneumonectomy from 1 January 2007 to 31 December 2015. Sarcopenia was assessed by the following CT-based parameters: cross-sectional total psoas area (TPA), cross-sectional total muscle area (TMA), and total parietal muscle area (TPMA), defined as TMA without TPA. Measures were performed at the level of the third lumbar vertebra and were obtained for the entire muscle surface, as well as by excluding fatty infiltration based on CT attenuation. Findings were stratified for gender, and a threshold of the 33rd percentile was set to define sarcopenia. Furthermore, we assessed the possibility of being sarcopenic at both the TPA and TPMA level, or not, by taking into account of not fatty infiltration. Five-year survival was 39.1% for the whole population. Lower TPA, TMA, and TPA were associated with lower survival at univariate analysis; taking into account muscular fatty infiltration did not result in more powerful discrimination. Being sarcopenic at both psoas and parietal muscle level had the optimum discriminating power. At the multivariable analysis, being sarcopenic at both psoas and parietal muscles (considering the whole muscle areas, including muscular fat), male sex, increasing age, and tumor stage, as well as Charlson Comorbidity Index (CCI), were independently associated with worse long-term outcomes. We conclude that sarcopenia is a powerful negative prognostic factor in patients with lung cancer treated by pneumonectomy.

scholarly journals Can smoking duration alone replace pack-years to predict the risk of smoking-related oncogenic mutations in non-small cell lung cancer? A cross-sectional study in Japan

BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e035615
Author(s):  
Koichi Ogawa ◽  
Yasuhiro Koh ◽  
Hiroyasu Kaneda ◽  
Motohiro Izumi ◽  
Yoshiya Matsumoto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cross Sectional Study ◽  
Small Cell ◽  
Sectional Study ◽  
Small Cell Lung ◽  
Cross Sectional ◽  
Oncogenic Mutations ◽  
Smoking Duration

ObjectiveTo investigate whether smoking duration alone can replace pack-years to predict the risk of oncogenic mutations in non-small cell lung cancer (NSCLC).DesignA cross-sectional study using the baseline dataset from the Japan Molecular Epidemiology for Lung Cancer Study.SettingForty-three medical institutions nationwide in Japan.ParticipantsFrom July 2012 to December 2013, 957 patients with newly diagnosed stage I–IIIB NSCLC who underwent surgery were enrolled, and molecular analyses were performed on 876 samples (from 441 ever-smokers and 435 never-smokers).Main outcomes measuredWe calculated the area under the receiver operating characteristic curve (AUC) values using logistic regression to compare between the predictive values of smoking duration and pack-years for mutational frequencies in the v-Ki-ras2 Kirsten rat sarcoma (KRAS), tumour suppressor p53 (TP53), and epidermal growth factor receptor (EGFR) genes and for cytosine-to-adenine base substitution (C>A).ResultsFor predicting KRAS mutations, the AUC values for smoking duration and pack-years were 0.746 (95% CI 0.682 to 0.800) and 0.759 (95% CI 0.700 to 0.810), respectively (p=0.058). For predicting KRAS mutations in smokers, the AUC values for smoking duration and pack-years were 0.772 (95% CI 0.697 to 0.833) and 0.787 (95% CI 0.714 to 0.845), respectively (p=0.036). There were no significant differences between the AUC values for smoking duration and pack-years in terms of predicting TP53 and EGFR mutations and C>A. Pack-years was a significantly better predictor of KRAS mutations than smoking duration.ConclusionSmoking duration was not significantly different from pack-years in predicting the likelihood of smoking-related gene mutations. Given the recall bias in obtaining smoking information, smoking duration alone should be considered for further investigation as a simpler alternative to pack-years.

Exhaled breath analysis in suspected cases of non-small-cell lung cancer: a cross-sectional study

2015 ◽  
Vol 9 (2) ◽  
pp. 027101 ◽  
Author(s):  
M Corradi ◽  
D Poli ◽  
I Banda ◽  
S Bonini ◽  
P Mozzoni ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Cross Sectional Study ◽  
Small Cell ◽  
Exhaled Breath ◽  
Sectional Study ◽  
Small Cell Lung ◽  
Cross Sectional ◽  
Exhaled Breath Analysis
Sign in / Sign up

Export Citation Format

Share Document